Effect of Cabergoline on Weight and Glucose Tolerance
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01395602|
Recruitment Status : Completed
First Posted : July 15, 2011
Last Update Posted : October 14, 2015
The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults.
This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks.
The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.
|Condition or disease||Intervention/treatment||Phase|
|Body Weight Impaired Glucose Tolerance in Obese||Drug: Cabergoline Other: placebo||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults|
|Study Start Date :||April 2002|
|Actual Primary Completion Date :||September 2003|
|Actual Study Completion Date :||July 2011|
Placebo Comparator: placebo
1 pill twice weekly
Active Comparator: cabergoline
cabergoline 0.5 mg twice weekly
- body weight [ Time Frame: 16 weeks ]
- glucose [ Time Frame: 16 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01395602
|United States, New York|
|New York, New York, United States, 10032|
|Principal Investigator:||Judith Korner, MD, PHD||Columbia University|